- Molecular NameDelapril
- SynonymNA
- Weight452.551
- Drugbank_IDN/A
- ACS_NO83435-66-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.15
- pkaN/A
- LogD (pH=7, predicted)-0.15
- Solubility (experiment)13 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.56
- LogSw (predicted, AB/LogsW2.0)0.19
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds12
- TPSA95.94
- StatusN/A
- AdministrationN/A
- PharmacologyAn ACE inhibitor.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed
- Caco_2N/A
- Bioavailability55.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAfter administration of delapril at a single dose of 60 mg, the predominant metabolite in the serum was M-I; it was followed by M-I11 as another active metabolite. The serum levels of M-11, an inactive metabolite, and of intact delapril were low. The serum levels of M-I peaked at 1.39 h and of M-I11 at 1.67 h after administration of delapril; they declined with a half-life of 1.2 1 and 0.8 1 h, respectively. Over 24 h after administration the total urinary recovery of delapril was 55.7%. M-I and M-I11 were excreted predominantly in the urine, whereas only small quantities of delapril and M-I1 were found there.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe antihypertensive effect of the drug was maintained in patients with essential hypertension during long-term treatment for more than 1 year without any increased incidence of side effects.
- LD50 (rat)LD50 (g/kg) p.o., i.p., s.c. 9.06, 0.22, 6.68 (male rats)
- LD50 (mouse)LD50 (g/kg) p.o., i.p., s.c. 3.40, 0.16, 2.34